The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Illumina Introduces Nextera® Exome and Custom Enrichment Sample Preparation Kits

<p class='bwalignc'> <i>Delivers fastest and easiest workflow with the lowest sample input for targeted resequencing studies</i> </p>

Tuesday, July 17, 2012

Illumina Introduces Nextera® Exome and Custom Enrichment Sample Preparation Kits06:30 EDT Tuesday, July 17, 2012 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ: ILMN) today introduced Nextera Exome and Custom Enrichment kits, the Company's latest targeted resequencing solutions offering sample preparation and enrichment in a single, integrated workflow. Leveraging the speed of Nextera technology and supporting the industry's lowest DNA sample input requirements (50 ng), the new kits enable researchers to quickly and economically perform a wide range of studies – from small, focused gene panels to full human exomes. Upfront sample preparation is an often difficult and time-consuming task for targeted resequencing studies. Nextera Exome and Custom Enrichment kits replace the lengthy sample preparation protocols with a single, streamlined workflow that can be performed in less than three hours and removes the requirement for mechanical DNA fragmentation. The kits integrate the ease of Nextera sample preparation with the company's established TruSeq® Exome and Custom Enrichment solutions for a fast, scalable and highly efficient approach to targeted resequencing. Offering excellent data quality with a low DNA sample input requirement, the kits enable researchers to study small samples, while retaining sufficient material for future analysis. “Nextera Enrichment kits deliver superior performance on all fronts with a simple, rapid workflow that eliminates almost an entire day of preparation time,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions. “Developed, tested, and optimized for Illumina sequencing platforms, Nextera Enrichment kits make targeted resequencing more broadly available to researchers who are interested in performing studies on DNA samples that may only be available in limited quantities.” "The combination of Nextera library prep and TruSeq capture produces a simple workflow and high quality data. It will allow us to process large numbers of samples without investing in automation systems and opens up capture-based sequencing to samples that would not have been accessible due to DNA input constraints,” said Dr. James Hadfield, Head of Genomics, Cancer Research, UK. “We have been able to perform custom and exome capture as well as low coverage genome sequencing from the same 50 ng input DNA." Nextera Exome Enrichment kits offer: Comprehensive coverage of the human exome, with greater than 62 Mb of both coding regions and untranslated regions (UTRs). Excellent data quality with high enrichment rates and premier coverage uniformity. The ability to fully customize content with Illumina's DesignStudio, a free online tool for Illumina customers. Industry-best DNA input of 50 ng. A unique 12-plex pre-enrichment sample pooling, reducing hands-on time and enabling the most cost-effective and operationally efficient workflow. Nextera Enrichment Sample Preparation Kits are now shipping. For more information, visit www.illumina.com/NexteraEnrich. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Illumina, Inc.Investors:Kevin Williams, MDInvestor Relations858-332-4989kwilliams@illumina.comorMedia:Jennifer TemplePublic Relations858-882-6822pr@illumina.com